Heis

UNIPLAT Welcoming New Member Patrick Tsang to Advisory Board: Unify Platform AG

Retrieved on: 
Wednesday, November 16, 2022
Unify, Duke, YPO, Technology, Hong, Bullying, Sustainable Development Goals, Leadership, United Kingdom, Patrick, COO, College, Blockchain, Investment, CFO, Racism, Science and technology in Asia, Heis, AI, Harvard Business School, Management, Satellite navigation device, Google

TOKYO, Nov. 16, 2022 /PRNewswire/ -- Unify Platform AG has announced that Patrick Tsang, Chairman of Tsangs Group, an innovation-focused global family office that bridges East and West, officially joined the advisory board of UNIPLAT, the world's first (*) online platform specialized for researchers and entrepreneurs focusing on SDGs-related fields, as one of the senior advisors on November 16, 2022.(*) Based on Google search results.

Key Points: 
  • Born and raised in the United Kingdom, Patrick Tsang encountered challenges andadversity, including racism and bullying.
  • "Anything is possible" is thepersonal motto of Patrick, and Tsangs Group is in the business of putting thatmotto into action every day.
  • Heis also a member of YPO Global One and a Founding Member of Monaco PrivateLabel Young Leaders.
  • Developed andmanaged by Unify Platform AG ( https://unify21.com/ ) which is based inSwitzerland, UNIPLAT's mission is to accelerate the success of the SDGs.

UNIPLAT Welcoming New Member Patrick Tsang to Advisory Board: Unify Platform AG

Retrieved on: 
Wednesday, November 16, 2022
Unify, Duke, YPO, Technology, Hong, Bullying, Sustainable Development Goals, Leadership, United Kingdom, Patrick, COO, College, Blockchain, Investment, CFO, Racism, Science and technology in Asia, Heis, AI, Harvard Business School, Management, Satellite navigation device, Google

TOKYO, Nov. 16, 2022 /PRNewswire/ -- Unify Platform AG has announced that Patrick Tsang, Chairman of Tsangs Group, an innovation-focused global family office that bridges East and West, officially joined the advisory board of UNIPLAT, the world's first (*) online platform specialized for researchers and entrepreneurs focusing on SDGs-related fields, as one of the senior advisors on November 16, 2022.(*) Based on Google search results.

Key Points: 
  • Born and raised in the United Kingdom, Patrick Tsang encountered challenges andadversity, including racism and bullying.
  • "Anything is possible" is thepersonal motto of Patrick, and Tsangs Group is in the business of putting thatmotto into action every day.
  • Heis also a member of YPO Global One and a Founding Member of Monaco PrivateLabel Young Leaders.
  • Developed andmanaged by Unify Platform AG ( https://unify21.com/ ) which is based inSwitzerland, UNIPLAT's mission is to accelerate the success of the SDGs.

Aristea Therapeutics Strengthens its Board of Directors with the Appointment of Three Accomplished Biopharma Leaders From Poseida Therapeutics, Novo Holdings and Pfizer

Retrieved on: 
Wednesday, August 24, 2022
CEO, BMS, Venture capital, University of Minnesota Law School, Pfizer, Amylin Pharmaceuticals, Science, Genetic engineering, Partner, Leadership, PPP, Patient, Circulatory system, Conditional sentence, Brigham and Women's Hospital, Bristol Myers Squibb, Degenerative disease, HS, Board, MIT, Immunology, Roche, Hospital, Medicine, Heis, Hidradenitis suppurativa, University, Partnership, CA, LP, Therapy, Tufts University School of Medicine, Inflammation, Investment, MD, Amgen, Acquisition, Drug development, Lists of diseases, Novo Holdings A/S, Center, Minot State University, CNS, Arena Pharmaceuticals, Pharmaceutical industry, Aristea, Gastroenterology, Director, Indiana University, Rheumatology, Neuroscience

Mr. Gergen will take an independent board seat, and Dr. O'Connell will take a seat on behalf of Novo Holdings.

Key Points: 
  • Mr. Gergen will take an independent board seat, and Dr. O'Connell will take a seat on behalf of Novo Holdings.
  • Heis currently the CEO of Poseida Therapeutics, a genetic engineering company developing novel cell and gene therapies with the capacity to cure.
  • Aristea Therapeutics (Air-iss-tay-uh) is a clinical-stage immunology focused drug development company developing novel therapies to treat serious inflammatory diseases.
  • In March 2022, Arena Pharmaceuticals was acquired by Pfizer Inc. As such, the partnership and the option to acquire Aristea now sit with Pfizer.

ValleyML Technology Foundation Announces the Winner of the ValleyML Distinguished Technical Achievement Award

Retrieved on: 
Wednesday, December 15, 2021
Texas A&M University, Algorithm, Technology, Human, SCM, AI, IEEE, Machine learning, TAMU, Software, Wi-Fi, SLAM, Heis, Communication, LDPC, Medical device

SANTA CLARA, Calif., Dec. 15, 2021 /PRNewswire/ --ValleyML Technology Foundation has announced that Dr. Kiran Gunnam has been named the recipient of the ValleyML Distinguished Technical Achievement Award .

Key Points: 
  • SANTA CLARA, Calif., Dec. 15, 2021 /PRNewswire/ --ValleyML Technology Foundation has announced that Dr. Kiran Gunnam has been named the recipient of the ValleyML Distinguished Technical Achievement Award .
  • The ValleyML Distinguished Technical Achievement Award honorsinnovators who have made lasting significant contributions to advanced computing and artificial intelligence technology for the broader benefit of humanity.
  • Dr. Gunnam will formally receive the ValleyML Distinguished Technical Achievement Award at ValleyML AI Expo.
  • ValleyML Technology Foundation is a California non-profit corporation whose mission is to use technology as the equalizer and strengthen humanity's shared voice through excellence awards.

Plexium Appoints Percival Barretto-Ko as President and Chief Executive Officer

Retrieved on: 
Thursday, November 4, 2021
Cornell University, SAN, LinkedIn, Strategic management, Cancer, Innovation, Yale University, MIT Sloan School of Management, TPD, Hoffmann-La Roche, Poverty, Master of Business Administration, Railway Executive Committee, Business administration, Astellas Pharma, Leadership, Government Affairs Institute, Senior, International, Protein, Transplant, Media, Board, Heis, CBO, EMEA, Corporate communication, Media contacts database, Neurodegeneration, Proteolysis targeting chimera, Infection, Biology, Sloan Fellows, Director, Executive Committee, Business development, Management

SAN DIEGO, Nov. 4, 2021 /PRNewswire/ --Plexium, Inc., (Plexium), a leading next-generation targeted protein degradation (TPD) company, today announced the appointment of experienced biopharmaceutical leader Percival Barretto-Ko as President and Chief Executive Officer and a member of the Board of Directors.

Key Points: 
  • SAN DIEGO, Nov. 4, 2021 /PRNewswire/ --Plexium, Inc., (Plexium), a leading next-generation targeted protein degradation (TPD) company, today announced the appointment of experienced biopharmaceutical leader Percival Barretto-Ko as President and Chief Executive Officer and a member of the Board of Directors.
  • "Percival is a highly accomplished veteran with the leadership, track record and breadth of experience that make him uniquely suited to lead Plexium," said Mike Grey, Executive Chairman of Plexium.
  • "I look forward to working with Percival to advance the company's promising drug discovery programs against challenging targets utilizing Plexium'sbest-in-classtechnology."
  • Barretto-Ko's earlier roles at Astellas include Senior Vice President, Head of International, and Senior Vice President, Corporate Strategy, Business Development & Government Affairs.